Eikon Therapeutics, Inc. EIKN Net proceeds from sales of subsidiary shares
Net proceeds from sales of subsidiary shares at other companies
Other financials
Where this comes from
Reported directly by Eikon Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceInitialPublicOffering.
The official record: Eikon Therapeutics, Inc. ’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Eikon Therapeutics, Inc. 's net proceeds from sales of subsidiary shares.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Eikon Therapeutics, Inc. 's net proceeds from sales of subsidiary shares?
- Eikon Therapeutics, Inc. (EIKN) reported net proceeds from sales of subsidiary shares of $349.03M in Q1 2026.